Corticosteroids can improve muscle function in boys with Duchenne muscular dystrophy and are commonly prescribed for newly diagnosed patients. Dr Michela Guglieri (Newcastle University, Newcastle upon Tyne, United Kingdom) discusses the current unmet needs in DMD, and the role of corticosteroids in the treatment paradigm of DMD.
The abstract entitled ‘Comparative Safety and Efficacy of Different Corticosteroid Regimens for Duchenne Muscular Dystrophy: Results of an International Randomized Controlled Trial’ was presented at the American Academy of Neurology (AAN) annual meeting, April 2-7, 2022.
- What are the current unmet needs in the treatment of Duchenne muscular dystrophy (DMD)? (0:15)
- What is the role of corticosteroids in the treatment paradigm for DMD? (1:45)
Disclosures: Michela Guglieri has received grant/research support from EC, NIH, PTC, and Sarepta; and has served on the advisory board for Dyne, Pfizer and NS Pharma; and has received honoraria/honorarium from Sarepta.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Neuromuscular Diseases
Anthony Béhin, EAN 2023: Highlights in myasthenia gravis
Dr Anthony Béhin (University Hospitals Pitié Salpêtrière, Paris, France) discusses highlights from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of myasthenia gravis. Disclosures: Anthony Béhin is a consultant for Alexion, Argenx, UCB, Sanofi and Ultragenyx pharmaceutical. He has received grant/research support from the Association Institut de Myologie and is on the […]
Luca Leonardi, EAN 2023: Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis
Dr Luca Leonardi (Sapienza University of Rome, Italy) summarizes the take-home messages from his study assessing skin biopsy as a marker of disease onset and severity in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a treatable disease. The abstract ‘EJoN: Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary […]
Sabrina Sacconi, EAN 2023: The MycarinG study – rozanolixizumab in the treatment of muscle-specific kinase autoantibody-positive myasthenia gravis
Muscle-specific kinase autoantibody-positive (MuSK-Ab+) generalised myasthenia gravis (gMG) is usually more clinically severe than acetylcholine receptor autoantibody-positive (AChR-Ab+) gMG. The Phase 3 MycarinG study analysed rozanolixizumab in patients with AChR-Ab+ or MuSKAb+ gMG. Dr Sabrina Sacconi (Côte d’Azur University, Nice, France) summarizes the take-home messages from her presentation of the results of the study. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!